Johnson & Johnson

...

Lilith Foster-Collins

By Lilith Foster-Collins

News Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


Johnson & Johnson said on Monday that it is acquiring the healthcare company Intra-Cellular for more than $14 billion.

Why It Matters

The purchase will allow Johnson & Johnson to delve further into the treatment of central nervous system disorders.

Read More on News

The purchase is one of several transactions in recent years to boost its pharmaceuticals and medical devices units, including a $13.1 billion deal for Shockwave Medical in 2024.

Antitrust laws, designed to promote competition and prevent monopolistic practices, are critical to maintaining free-market dynamics in industries where large companies wield substantial influence. Johnson & Johnson, a multinational corporation known for its healthcare products, exemplifies how such regulations apply to businesses of significant scale. These laws aim to curb anti-competitive behaviors, such as price-fixing, market allocation, and monopolistic mergers. As scrutiny of corporate practices intensifies globally, companies like Johnson & Johnson, along with others in pharmaceutical and consumer goods sectors, face increasing regulatory oversight to ensure compliance and protect consumer interests.

What To Know

Johnson & Johnson will acquire Intra-Cellular for $132 per share in cash, a 39 percent premium over Intra-Cellular's Friday closing price of $94.87.

Following the announcement, shares of both companies rose Monday.

Johnson & Johnson

...

Intra-Cellular, based in Bedminster, New Jersey, surged about 34 percent to $127.10, while J&J's stock climbed 1 percent to $143.45.

What Is Intra-Cellular?

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression, which generated $175 million in third-quarter revenue last year, with a 38 percent rise in total prescriptions.

The company recently expanded its sales force to target growth opportunities with primary care doctors.

It is also seeking FDA approval to use Caplyta as a supplemental treatment for major depressive disorder and has a drug pipeline that includes a potential treatment for anxiety, psychosis, and Alzheimer's-related agitation, currently in mid-stage trials.

J&J to Finance Using Cash and Debt

J&J will finance the $14.6 billion deal using cash and debt, with expectations to close later this year.

The acquisition announcement came days after Intra-Cellular settled a patent lawsuit, allowing Sandoz Inc. to introduce a generic version of Caplyta in 2040 or possibly earlier.

The deal has been submitted for federal regulatory review, with other patent cases still pending in court.

What People Are Saying

RBC Capital analyst Shagun Singh told Reuters that the deal fits strategically into J&J's neurological drugs division, an important area for the company.

Jeff Jonas, portfolio manager at Gabelli Funds, told Reuters that the acquisition could potentially face a tougher antitrust review.

"I do have a lot of antitrust concerns about this deal," he said.

Gabelli Funds owns about 193,035 shares of J&J.

Jonas said there was an overlap in the products of the two companies.

J&J already has a late-stage depression drug and a schizophrenia treatment on the market.

What Happens Next

The acquisition could potentially face regulatory review before finalization.

This article includes reporting from the Associated Press

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines